Replimune Wins FDA Accelerated Nod For TUDRIQEVTM In Advanced Melanoma

Replimune Group received FDA accelerated approval for TUDRIQEVTM in combination with nivolumab (Bristol Myers Squibb) for adults with unresectable advanced cutaneous melanoma whose disease progressed after anti-PD-1 therapy. The approval is a major regulatory milestone supporting commercialization prospects and likely to be a positive catalyst for REPL.

Analysis

Replimune Group received FDA accelerated approval for TUDRIQEVTM in combination with nivolumab (Bristol Myers Squibb) for adults with unresectable advanced cutaneous melanoma whose disease progressed after anti-PD-1 therapy. The approval is a major regulatory milestone supporting commercialization prospects and likely to be a positive catalyst for REPL.